Table 2.
Background Medical Therapy by Diastolic Dysfunction Status
| Diastolic Dysfunction Absent (N=101) | Diastolic Dysfunction Present (N=94) | P Value | |
|---|---|---|---|
| Active Non-HIV Related Medications | |||
| Any diuretic | 13 (13) | 17 (18) | 0.31 |
| ACEI | 16 (16) | 23 (24) | 0.13 |
| ARB | 2 (2) | 7 (7) | 0.09 |
| Beta-blocker | 8 (8) | 13 (14) | 0.18 |
| Any antiplatelet | 9 (9) | 19 (18) | 0.04 |
| Lipid lowering therapy | 31 (32) | 45 (49) | 0.02 |
| Insulin | 5 (5) | 5 (5) | 1.00 |
| Oral glucose lowering therapy | 9 (9) | 17 (18) | 0.06 |
| Active HIV Medications | |||
| ≥2 class ART regimen | 58 (57) | 63 (67) | 0.17 |
| NRTI or multiple NRTI | 42 (42) | 34 (37) | 0.47 |
| NNRTI | 5 (5) | 8 (9) | 0.32 |
| Protease inhibitor | 25 (25) | 17 (18) | 0.27 |
| Integrase Inhibitor | 25 (25) | 22 (24) | 0.86 |
| Prior HIV Medications* | |||
| ≥2 class ART regimen | 34 (35) | 39 (43) | 0.25 |
| NRTI or multiple NRTIb | 46 (46) | 64 (70) | 0.01 |
| NNRTI | 15 (15) | 16 (18) | 0.70 |
| Protease inhibitor | 38 (38) | 45 (50) | 0.11 |
| Integrase Inhibitor | 19 (20) | 17 (19) | 0.90 |
Data presented as n (%)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.
*
Describes medications patients received in the past but no longer receiving at time of study baseline.